Phath­om Phar­ma­ceu­ti­cals snatch­es up an­oth­er Cel­gene ex­ec; True North bets $74M for a stake in Bio­con Bi­o­log­ics

6 years ago
News Briefing

UCSD sci­en­tist­s' mouse study spot­lights pos­si­ble path to an ALS gene ther­a­py

6 years ago
R&D

Chi­nese in­vestors spear­head a $90M raise for res­pi­ra­to­ry biotech's pipeline build­ing

6 years ago
R&D

Mer­ck KGaA, Pfiz­er's Baven­cio set to seal blad­der can­cer ap­proval af­ter con­fir­ma­to­ry tri­al scores

6 years ago
R&D

Mod­er­na CEO Ban­cel ac­knowl­edges a set­back, but stays fo­cused on an up­beat as­sess­ment of 2019

6 years ago
R&D

The first biotech IPO of the new decade has land­ed — and of course it's an­oth­er can­cer drug de­vel­op­er

6 years ago
Financing
R&D

As ques­tions swirl around lead drug, Fi­bro­Gen (and As­traZeneca) find a new cham­pi­on from Big Phar­ma

6 years ago
People
R&D

Mer­ck dives deep­er in­to KRAS, team­ing up with Tai­ho, As­tex to de­vel­op small mol­e­cule drugs

6 years ago
Deals

The list gets longer: Mer­ck, Al­ler­gan, No­var­tis is­sue 2020 drug price hikes — re­port

6 years ago
Pharma

FDA of­fers As­traZeneca a short­cut on a land­mark SGLT2 ap­proval while Chi­na green­lights Lokel­ma

6 years ago
Pharma
FDA+

FDA rushed to ap­prove new drugs in 2019, some­times way ahead of sched­ule. Could that be dan­ger­ous?

6 years ago
FDA+

J&J drops its op­tion on Proven­tion Bio drug af­ter tri­al fail­ure

6 years ago
R&D

IQVIA vet takes the helm at Chi­na's Foun­tain Med­ical; Michael Nazak pro­mot­ed to CFO post at Aridis

6 years ago
Peer Review

Clin­i­cal un­cer­tain­ty, price push­es UK's NICE to spurn Akcea's Waylivra

6 years ago
FDA+

Bank­rupt uBio­me sells off patents, da­ta for $7M; J&J buys op­tions on Pul­ma­trix's lung can­cer drugs

6 years ago
News Briefing

Re­gen­eron brings out the bud­get ax as ex­ecs cut staff in the wake of re­vis­ing al­liance with Sanofi

6 years ago
R&D

Il­lu­mi­na's $1.2B buy­out dies amid FTC 'mo­nop­o­list' ac­cu­sa­tion

6 years ago
Deals

Of­fer­ing much need­ed re­lief for Wood­ford-as­so­ci­at­ed funds, se­quenc­ing uni­corn Ox­ford Nanopore rais­es $105.9M in new ...

6 years ago
Financing

Cash-strapped No­van takes a hard knock as mol­lus­cum drug fiz­zles in late-stage tri­als

6 years ago
R&D

In­cyte takes a beat­ing as a key PhI­II study flops in their lat­est painful set­back — block­buster hopes crushed

6 years ago
R&D

BeiGene scores first Chi­na OK with PD-1 — to be man­u­fac­tured by Boehringer In­gel­heim

6 years ago
China
Pharma

Durect shares stum­ble as top drug fails mid-stage tri­al

6 years ago
R&D

New year, new (high­er) drug prices

6 years ago
Pharma

Tough times for Tecen­triq as NICE once again slaps down Roche's im­munother­a­py — slight ben­e­fit not worth price

6 years ago
R&D
First page Previous page 866867868869870871872 Next page Last page
A service from the Financial Times